

HIPRABOVIS SOMNI/Lkt emulsion for injection for cattle

Authorised

- Mannheimia haemolytica, Serotype A1, Strain 2806, Leucotoxoid
- Histophilus somni, strain Bailie, Inactivated

Product identification

Medicine name:

HIPRABOVIS SOMNI/Lkt emulsion for injection for cattle

Active substance:

Mannheimia haemolytica, Serotype A1, Strain 2806, Leucotoxoid
Histophilus somni, strain Bailie, Inactivated

Target species:

Cattle

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Mannheimia haemolytica, Serotype A1, Strain 2806, Leucotoxoid
2.80 enzyme-linked immunosorbent assay unit / 1.00 Dose

Histophilus somni, strain Bailie, Inactivated
3.30 other / 1.00 Dose

Pharmaceutical form:

Emulsion for injection

Withdrawal period by route of administration:

Subcutaneous use:

-

Cattle

- Meat and offal. 0 day
 - Milk. 0 day
-

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI02AB

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Denmark

Package description:

The container consists of 100 ml (50 doses) Type II colourless glassvials, Type I rubber stoppers and aluminium caps. Package sizes:- Cardboard box with one glass bottle of 50 doses with a rubber stopper and aluminium cap.

The container consists of 20 ml (10 doses) Type I colourless glass vials, Type I rubber stoppers and aluminium caps. Package sizes:- Cardboard box with one glass vial of 10 doses with a rubber stopper and aluminium cap.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Laboratorios Hipra S.A.

Marketing authorisation date:

25/01/2007

Manufacturing sites for batch release:

Laboratorios Hipra S.A.

Responsible authority:

Danish Medicines Agency

Authorisation number:

39920

Date of authorisation status change:

25/01/2007

Reference member state:

Ireland

Procedure number:

IE/V/0186/001

Concerned member states:

Austria Belgium Cyprus Czechia Denmark Estonia Finland France Germany
Greece Hungary Italy Latvia Lithuania Luxembourg Netherlands Poland
Portugal Slovakia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 16/01/2026

Updated on: 14/03/2026

[Download](#)